Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication
- PMID: 23106926
- PMCID: PMC4268864
- DOI: 10.1111/j.1360-0443.2012.04038.x
Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication
Abstract
Aim: To identify factors that predict the expression of neonatal abstinence syndrome (NAS) in infants exposed to methadone or buprenorphine in utero.
Design and setting: Multi-site randomized clinical trial in which infants were observed for a minimum of 10 days following birth, and assessed for NAS symptoms by trained raters.
Participants: A total of 131 infants born to opioid dependent mothers, 129 of whom were available for NAS assessment.
Measurements: Generalized linear modeling was performed using maternal and infant characteristics to predict: peak NAS score prior to treatment, whether an infant required NAS treatment, length of NAS treatment and total dose of morphine required for treatment of NAS symptoms.
Findings: Of the sample, 53% (68 infants) required treatment for NAS. Lower maternal weight at delivery, later estimated gestational age (EGA), maternal use of selective serotonin re-uptake inhibitors (SSRIs), vaginal delivery and higher infant birthweight predicted higher peak NAS scores. Higher infant birthweight and greater maternal nicotine use at delivery predicted receipt of NAS treatment for infants. Maternal use of SSRIs, higher nicotine use and fewer days of study medication received also predicted total dose of medication required to treat NAS symptoms. No variables predicted length of treatment for NAS.
Conclusions: Maternal weight at delivery, estimated gestational age, infant birthweight, delivery type, maternal nicotine use and days of maternal study medication received and the use of psychotropic medications in pregnancy may play a role in the expression of neonatal abstinence syndrome severity in infants exposed to either methadone or buprenorphine.
Trial registration: ClinicalTrials.gov NCT00271219.
© 2012 The Authors, Addiction © 2012 Society for the Study of Addiction.
Conflict of interest statement
This study was funded by the National Institute on Drug Abuse. No contractual constraints on publishing were imposed by the funding body.
The clinical trial was registered with
H.J. discloses that she has received reimbursement for time and travel from Reckitt Benckiser.
References
-
- National Institutes of Health Consensus Development Panel. Effective medical treatment of opiate addiction. JAMA. 1998;280:1936–43. - PubMed
-
- Fajemirokun-Odudeyi O, Sinha C, Tutty S, Pairaudeau P, Armstrong D, Phillips T, et al. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol. 2006;126:170–5. - PubMed
-
- Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy: Effects and management. Obstet Gynecol Clin North Am. 1998;25:139–51. - PubMed
-
- Jarvis MA, Schnoll SH. Methadone treatment during pregnancy. J Psychoactive Drugs. 1994;26:155–61. - PubMed
-
- Finnegan LP, Kaltenbach K. Neonatal abstinence syndrome. In: Hoekelman RA, Friedman SB, Nelson NM, Seidel HM, editors. Primary pediatric care. 2. St Louis MO: Mosby Year Book; 1992. pp. 1367–78.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- R01 DA 015738/DA/NIDA NIH HHS/United States
- R01 DA 018417/DA/NIDA NIH HHS/United States
- R01 DA 15832/DA/NIDA NIH HHS/United States
- R01 DA015764/DA/NIDA NIH HHS/United States
- R01 DA 015778/DA/NIDA NIH HHS/United States
- M01 RR 00095/RR/NCRR NIH HHS/United States
- R01 DA 015741/DA/NIDA NIH HHS/United States
- R01 DA 015764/DA/NIDA NIH HHS/United States
- M01 RR000095/RR/NCRR NIH HHS/United States
- R01 DA 018410/DA/NIDA NIH HHS/United States
- R01 DA015738/DA/NIDA NIH HHS/United States
- M01 RR000109/RR/NCRR NIH HHS/United States
- M01 RR 109/RR/NCRR NIH HHS/United States
- R01 DA 017513/DA/NIDA NIH HHS/United States
- R01 DA018417/DA/NIDA NIH HHS/United States
- R01 DA018410/DA/NIDA NIH HHS/United States
- R01 DA015778/DA/NIDA NIH HHS/United States
- R01 DA015832/DA/NIDA NIH HHS/United States
- R01 DA015741/DA/NIDA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical